Latest Veterans News

Keysight Technologies has tapped long-time finance executive Jason Kary to replace CFO Neil Dougherty, who is stepping down for personal reasons. The company has left its fiscal fourth-quarter outlook unchanged ahead of results on November 19.

Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.

Mach7 Technologies has completed a costly FY26 reset, cutting operating expenditure by 16% while revenue fell 17% and the net loss widened to A$8.9 million. The company enters FY27 with a higher recurring-revenue mix, new customer orders and A$19.9 million in cash, but no earnings guidance and plenty to prove.

Emyria has reported record quarterly revenue of approximately $1.42 million after opening its first Sydney Empax clinic and expanding national treatment capacity. The growth comes with $2.28 million in operating cash outflows and an estimated 2.08 quarters of funding at quarter-end.

Thrive Tribe Technologies has made progress on its defence and veteran software ambitions, but ended September with just A$20,000 in cash after a A$573,000 operating outflow. Its proposed A$2 million placement remains uncommitted and requires shareholder approval in November.

4DMedical reported a record first quarter, with scan volumes up 61% to 119,672 and unaudited operating revenue rising 66% to $2.3 million. New contracts across the US, Germany and Australia broaden the commercial story, while $242.8 million in cash gives the company room to keep investing.

Mach7 Technologies has delivered its first positive first-quarter operating cash flow, while ARR rose 8.5% in constant currency to A$23.5 million. The next test is whether increased product investment and the Flamingo rollout can translate into contracted sales.

Pacific Edge has secured new US payer access and a Veterans Administration purchasing agreement while proposed Medicare price increases could materially lift revenue per test. The recovery remains unfinished, however, with US commercial volumes down 13% and final Medicare coverage still pending.

Biotron has appointed Glenn Gilbert as chief executive and executive director, bringing more than two decades of pharmaceutical, medical device and diagnostics experience to the company’s SedRx and antiviral programs. His package combines a $250,000 salary with up to 100 million performance-based options and $230,000 in milestone-linked cash bonuses.

Emyria’s FY26 annual report shows a rapidly expanding psychedelic-assisted care network, with revenue up 210% and treatment capacity reaching 18 beds across four states. The gains came alongside a larger loss, $4.6 million in operating cash outflow and an auditor-highlighted material uncertainty over the company’s ability to continue without further funding.

Thrive Tribe Technologies has repositioned WooBoard and REFFIND towards defence and workforce software, but its FY26 annual report flags a material uncertainty over the company’s ability to continue as a going concern. The pivot follows a $3.66 million loss, $2.57 million operating cash outflow and another $1 million placement after year-end.

TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.